Catherine E. Willoughby

Sobre mí

Publicaciones destacadas

• Atezolizumab plus bevacizumab: a novel breakthrough in hepatocellular carcinoma

  Autores:

  Castet F; Willoughby CE; Haber PK; Llovet JM ;

  Referencia: Clinical Cancer Research 2021.

• Copy number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma

  Autores:

  Bassaganyas L; Pinyol R; Esteban-Fabró R; Torrens L; Torrecilla S;

  (...)

  Montal R; Mazzaferro V; Camps J; Sia D; Llovet JM .

  Ver listado completo de autores

  Referencia: Clinical Cancer Research 2020.

• Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

  Autores:

  Willoughby CE; Jiang Y; Thomas HD; Willmore E; Kyle S;

  (...)

  Cano C; Newell DR; Reeves HL; Ryan AJ; Wedge SR .

  Ver listado completo de autores

  Referencia: Journal Of Clinical Investigation 2020.

• Neutrophils - driving progression and poor prognosis in hepatocellular carcinoma?

  Autores:

  Margetts J; Ogle LF; Chan SL; Chan AWH; Chan KCA;

  (...)

  Mann DA; Wilson CL; Manas DM; Yeo W; Reeves HL .

  Ver listado completo de autores

  Referencia: British Journal Of Cancer 2018.

• Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for Hepatocellular Carcinoma?

  Autores:

  Ogle LF; Orr JG; Willoughby CE; Hutton C; McPherson S;

  Plummer R; Boddy AV; Curtin NJ; Jamieson D; Reeves HL .

  Referencia: Journal Of Hepatology 2016.

• Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?

  Autores:

  Willoughby, Catherine E.; Reeves, Helen L.;;

  Referencia: Chin Clin Oncol 2016.

• DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival

  Autores:

  Cornell, Liam; Munck, Joanne M.; Alsinet, Clara; Villanueva, Augusto; Ogle, Laura;

  (...)

  Rose, John; Manas, Derek M.; Shapiro, Geoffrey I.; Curtin, Nicola J.; Reeves, Helen L.;.

  Ver listado completo de autores

  Referencia: Clinical Cancer Research 2015.

Proyectos destacados

• PROJECT RESEARCHER: Discovery of biomarkers predictors of response and/or resistance to anti-PD1-based immune checkpoint inhibitors in advanced HCC.

  Investigador/a principal: Josep M Llovet

  Duración: 15/12/2018

• PROJECT RESEARCHER: Impact of cabozantinib alone or in combination with anti-PD1 on the immune system in HCC and assessment of the synergistic anti-tumoral effect in experimental models.

  Investigador/a principal: Josep M Llovet

  Duración: 03/12/2018 - 01/04/2020

• PROJECT RESEARCHER: HUNTER: Hepatocellular Carcinoma Expediter Network.

  Investigador/a principal: Derek Mann, Helen L Reeves, Josep M Llovet

  Duración: 01/12/2018 - 30/11/2022

• PRINCIPAL INVESTIGATOR: Post-Thesis Submission Scholarship - Preclinical modelling of hepatocellular carcinoma and novel strategies for therapeutic intervention.

  Investigador/a principal: Catherine E Willoughby

  Duración: 20/11/2017 - 20/02/2018

• LEAD INVESTIGATOR: PhD Studentship - Preclinical modelling of hepatocellular carcinoma and novel strategies for therapeutic intervention.

  Investigador/a principal: Helen Reeves, Stephen Wedge

  Duración: 01/10/2013 - 30/09/2017